Novel Raman Imaging Reveals How TJ0113 Drug Rescues Liver Failure Through Mitophagy

Acute liver failure (ALF) is a medical emergency with high mortality rates, often caused by drug toxicity and characterized by severe mitochondrial dysfunction. This groundbreaking study introduces both a novel therapeutic compound and an innovative detection method that could transform liver disease treatment.

Researchers investigated TJ0113, a derivative of the mitophagy inducer UMI-77, using thioacetamide-induced liver failure in mice. The key innovation was employing aberration-free line-scanning confocal Raman imaging (AFLSCRI) to monitor mitochondrial changes in real-time without invasive procedures or fluorescent labels. This system achieved 2 μm spatial resolution and detection speeds 100 times faster than conventional methods.

TJ0113 demonstrated remarkable protective effects by enhancing mitophagy through PINK1/Parkin and ATG5 pathways. The drug selectively removed damaged mitochondria while preserving healthy ones, reducing hepatocyte death by 60% and significantly improving survival rates. Metabolomics revealed that TJ0113 restored normal lipid and amino acid metabolism, while RNA sequencing showed it modulated the PI3K/AKT signaling pathway. Importantly, the Raman imaging could detect these mitochondrial improvements in blood samples, liver tissue, and even muscle tissue.

The clinical implications are substantial. Current mitochondrial function tests require tissue samples and fluorescent probes that can interfere with normal cellular processes. This Raman-based approach offers real-time, bedside monitoring of mitochondrial health during treatment. The technology showed over 90% sensitivity and specificity, with excellent correlation to traditional histological findings. This could enable personalized dosing, early detection of treatment response, and better patient outcomes in liver disease and other conditions involving mitochondrial dysfunction.